Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
- Andrea Greif
Senior Director, Communications
(914) 821-8958
andrea.greif@lls.org
LLS Commits $1 Million to Blood Cancer Patients Impacted by Hurricane Harvey
Rye Brook, NY – September 5, 2017 – In the wake of the destruction caused by Hurricane Harvey, The Leukemia & Lymphoma Society (LLS) announced today that it will donate up to $1 million to help blood cancer patients who have been impacted by the storm. Blood cancer patients living in declared disaster areas impacted by Hurricane Harvey, are eligible to receive $500 to help with cancer-related necessities s...
FDA Approval of AML Therapy is a Significant Advance for Blood Cancer Patients
Rye Brook, N.Y. (September 1, 2017) – The steady march of progress in new treatments for patients with acute myeloid leukemia (AML), one of the most deadly blood cancers which takes more than 10,000 lives in the U.S. each year, continues today with the U.S. Food & Drug Administration approval of gemtuzumab ozogamicin (Mylotarg®). After four decades of little progress for this lethal disease, today’s ...
Survey Reveals Striking Lack of Knowledge of Major Cancer Killer
View full multimedia release here. Rye Brook, NY (August 31, 2017) – Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system. A new survey commissioned by The Leukemia &...
LLS Investment Pays Off: FDA Approves Immunotherapy for Blood Cancer Patients
Rye Brook, N.Y. (August 30, 2017) – Today heralds a new era in cancer treatment with the U.S. Food and Drug Administration (FDA) approval of a new, cutting-edge gene therapy that reprograms a patient’s immune system to find and kill cancer cells. This highly personalized therapy known as Kymriah (previously CTL019 or tisagenlecleucel-T) signifies the promise of CAR (chimeric antigen receptor) T-cell im...
FDA Approval: LLS Applauds New Advance for Acute Lymphoblastic Leukemia
RYE BROOK, N.Y. (August 17, 2017) – The Leukemia & Lymphoma Society (LLS) applauds today’s approval by the U.S. Food and Drug Administration (FDA) of inotuzumab ozogamicin (Besponsa®) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This year alone, it is estimated that almost 6,000 people in the United States will be diagnosed with ALL. Thi...
More than 20 Years Helping Cancer Patients and Saving Lives
See multimedia release here. RYE BROOK, N.Y. (August 8, 2017) – Where can I get good information about my cancer and treatments? Should I get a second opinion? Is there anyone I can talk with who has been through this? Where can I get financial assistance to help cover the cost of my treatment? How do I talk with my loved ones and children about my disease? These are just a few of the hundreds of questions...
LLS Applauds Another Advance for Blood Cancer Patients
August 3, 2017 (Rye Brook, NY) - The Leukemia & Lymphoma Society (LLS) applauds the U.S. Food and Drug Administration (FDA) approval today of CPX-351 (VyxeosTM), an innovative combination of two chemotherapy drugs being used to treat two high-risk subgroups of acute myeloid leukemia (AML) patients. After more than four decades of little progress in treating AML, this approval marks the third drug appr...
FDA Approves New Targeted Therapy for AML
Rye Brook, N.Y. (August 1, 2017) – Today marks another significant advance in the offensive against acute myeloid leukemia (AML), one of the most deadly blood cancers that takes more than 10,000 lives in the U.S. each year. The Leukemia & Lymphoma Society (LLS) applauds The U.S. Food & Drug Administration’s approval today of a new targeted therapy, enasidenib (IDHIFA®), for patients with AML, who ha...